Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease

NCT02768662 is registered in ClinicalTrials.gov with Otonomy, Inc. as lead sponsor.

NCT NCT02768662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02768662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Lead sponsor
Otonomy, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
August 31, 2016
Completion date
September 30, 2017
Enrollment
142 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

meniere's disease